1. No difference in bleeding risk between subcutaneous enoxaparin and heparin for thromboprophylaxis in end-stage renal disease 
Kevin E. Chan, Ravi I. Thadhani, Franklin W. Maddux 
Kidney International 
Volume 84, Issue 3, Pages (September 2013)
DOI: /ki
Copyright © 2013 International Society of Nephrology Terms and Conditions

2. Figure 1
Crude thrombosis and bleeding rate in end-stage renal disease (ESRD) patients initiated on subcutaneous enoxaparin or heparin for thromboprophylaxis. Unadjusted rates with 95% confidence intervals were calculated using Poisson regression. pt, patient.
Kidney International  , DOI: ( /ki )
Copyright © 2013 International Society of Nephrology Terms and Conditions